Susquehanna International Group
PRLD icon

Susquehanna International Group’s Prelude Therapeutics PRLD Stock Holding History

Susquehanna International Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,500
Closed -$94.3K – 13905
2025
Q4 		$94.3K Buy
+32,500
New +$54.8K ﹤0.01% 11487

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group's PRLD Position: Q1 2026 in Review

Susquehanna International Group increased its Prelude Therapeutics (PRLD) stake by 97% in Q1 2026, buying an estimated $346K and bringing the position to 267,788 shares worth $916K. The position accounts for ﹤0.01% of the portfolio, ranked #8110.

Susquehanna International Group first reported a position in PRLD in Q2 2021 and has held it in 12 quarters since. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Susquehanna International Group held 267,788 shares of Prelude Therapeutics worth $916K as of Q1 2026.
  • Susquehanna International Group bought 131,879 Prelude Therapeutics shares in Q1 2026, an estimated $346K.
  • Prelude Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8110 holding.
  • Susquehanna International Group first reported a position in Prelude Therapeutics in Q2 2021 and has held it in 12 quarters since.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.